TGF-beta inhibitors and methods
OwnerRajendra S. Bhatnagar, Craig A. Gough +1inventors
InventorsRajendra S. Bhatnagar, Craig A. Gough, Jing Jing Qian
Life of this patent
Estimating the term…
Abstract
A family of small peptides have been found to be inhibitory to TGF-β activity, and preferably have the primary structure of Formula 1: Formula I AA1-AA2-AA3-Pro-D-Glu-Ala wherein AA1 is leucine, phenylalanine, α-aminoisobutric acid, N-methylalanine, N-methylisoleucine, or isoleucine; AA2 is the same or a different amino acid residue as in AA1; and AA3 is alanine or N-methylalanine.
Claims16
A peptide having the primary structure of Formula I
- AA1-AA2-AA3-Pro-D-Glu-Ala Formula I
- wherein AA1 is leucine, phenylalanine, α-aminoisobutric acid, N-methylalanine, N-methylisoleucine, or isoleucine;
- AA2 is the same or a different amino acid residue as in AA1;
- and AA3 is alanine or N-methylalanine.
The peptide Leu-Ile-Ala-Pro-D-Glu-Ala.
The peptide Phe-Ile-Ala-Pro-D-Glu-Ala.
The peptide Leu-Phe-Ala-Pro-D-Glu-Ala.
A therapeutic composition, comprising:
- AA1-AA2-AA3-Pro-D-Glu-Ala Formula I
- wherein AA1 is leucine, phenylalanine, α-aminoisobutric acid, N-methylalanine, N-methylisoleucine, or isoleucine, AA2 is the same or a different amino acid residue as in AA1;
- and AA3 is alanine or N-methylalanine;
- and,
- a physiologically acceptable carrier.
A method of inhibiting TGF-β, comprising:
- administering to a patient in need thereof an effective activity-inhibiting amount of a peptide specific against a fibrotic growth factor, the peptide having the primary structure
- AA1-AA2-AA3-Pro-D-Glu-Ala Formula I
- wherein AA, is leucine, phenylalanine, α-aminoisobutric acid, N-methylalanine, N-methylisoleucine, or isoleucine;
- AA2 is the same or a different amino acid residue as in AA1;
- and AA3 is alanine or N-methylalanine.
Dependencies are inferred from the claim text.